Beam Therapeutics (BEAM) Moves 15.6% Higher: Will This Strength Last?Zacks Investment Research • Thursday
Beam Therapeutics Inc. (BEAM) Reviews Initial Phase I II BEAM-301 Data in Glycogen Storage Disease Type 1a TranscriptSeeking Alpha • Tuesday
Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual CongressGlobeNewsWire • Tuesday
Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead?The Motley Fool • 10/18/26
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Beam Therapeutics Inc. - BEAMPRNewsWire • 10/15/26
Beam Therapeutics to Present Initial Data from Phase 1/2 Trial of BEAM-301 in Glycogen Storage Disease Type Ia (GSDIa) at the ESGCT 33rd Annual CongressGlobeNewsWire • 10/13/26
BEAM Investors Have Opportunity to Join Beam Therapeutics Inc. Fraud Investigation with SBS LawBusiness Wire • 09/16/26
Beam Therapeutics Inc. (BEAM) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/09/26
Beam Therapeutics Inc. (BEAM) Discusses Updated Phase 1/2 Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency TranscriptSeeking Alpha • 09/08/26
Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026GlobeNewsWire • 09/08/26
Beam Therapeutics to Participate in Upcoming September 2026 Investor ConferencesGlobeNewsWire • 08/31/26
BEAM's Q2 Loss Wider Than Expected, Revenues Fall Y/Y, Pipeline in FocusZacks Investment Research • 08/05/26
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/04/26
Beam Therapeutics Reports Second Quarter 2026 Financial Results and Announces First Patient Dosed in Global Pivotal Cohort of BEAM-302 Trial in Alpha-1 Antitrypsin Deficiency (AATD)GlobeNewsWire • 08/04/26